An adaptor protein FRS2b inhibits epidermal growth factor-receptor (EGFR) tyrosine kinase without being phosphorylated at tyrosine residues after EGF stimulation. Although binding to ERK appears to be important for this inhibition, the precise molecular mechanisms and the role of FRS2b in signal transduction mediated by other EGFR family members, as well as its role in human cancer, remain unclear. In this study, we demonstrate that FRS2b inhibits anchorage-independent cell growth induced by oncogenic ErbB2, another member of EGFR family, and that it inhibits heterodimer formation between EGFR and ErbB2. We mapped the residues important for the FRS2b and ERK interaction to two docking (D) domain-like sequences on FRS2b and two aspartic acid residues in the common docking (CD) domain of ERK. Moreover, in response to EGF, ERK translocated to the plasma membrane in cells expressing FRS2b but not an FRS2b mutant in which four arginine residues in the D domains were replaced with alanines, suggesting that FRS2b serves as a plasma membrane anchor for activated ERK. Finally, a low mRNA expression level of FRS2b was significantly correlated with poor prognosis in a cohort of 60 non-small cell lung cancer patients. Therefore, we have identified the molecular mechanisms by which FRS2b acts as a feedback inhibitor of EGFR family members and suggest a role for FRS2b as a tumor suppressor.
Introduction
Signal transduction pathways mediated by members of epidermal growth factor-receptor (EGFR) tyrosine kinase family, including EGFR and ErbB2, have pivotal roles in numerous physiological and pathological processes (Blume-Jensen and Hunter, 2001; Yarden and Sliwkowski, 2001 ). Upon stimulation with EGF, these receptors dimerize and are phosphorylated on their tyrosine residues to activate complex signaling networks. Increasing evidence has indicated the importance of EGFR family members in the development of various malignancies. As the unregulated activation of these networks can result in malignancy, these signaling networks must be coordinated in a fine-tuned manner under physiological conditions. Emerging evidence indicates that many negative regulators of these signaling pathways exist and that these regulate signaling networks through multiple modes of action (Gotoh, 2009 ). The coordinated actions of both positive and negative regulators qualitatively and quantitatively fine-tune signaling under physiological conditions.
FRS2b also termed SNT-2 or FRS3, belongs to the FRS2 family of docking scaffolding adaptor proteins (Schlessinger, 2000; Eswarakumar et al., 2005; Gotoh, 2008; Sato and Gotoh, 2009 ). This family comprises two members: FRS2a and FRS2b. Both contain N-terminal myristylation sites, resulting in a plasma membrane distribution, and a phosphotyrosine-binding domain, which allows for binding to a limited number of receptor tyrosine kinases including fibroblast growth factor receptor and nerve growth factor receptor. The activation of these receptor tyrosine kinases induces the phosphorylation of the FRS2 family members at tyrosine residues, thereby allowing binding to Grb2 and Shp2, an SH2 domain-containing adaptor protein and a tyrosine phosphatase, respectively. Subsequently, Shp2 activates the Ras/ERK pathway, and Grb2 activates the Ras/ERK, phosphatidylinositol 3-kinase and ubiquitinylation/degradation pathways by binding to SOS, Gab1 and Cbl, respectively, through the SH3 domains of Grb2. Although it is well-known that FRS2a acts as a central mediator in fibroblast growth factor signaling, the functions of FRS2b are still unclear (Hadari et al., 2001; Gotoh et al., 2004a; Yamamoto et al., 2005) . FRS2b compensates for the loss of FRS2a and activates ERK in response to fibroblast growth factor in Frs2aÀ/À mouse embryonic fibroblasts (Gotoh et al., 2004b) .
We have previously shown that FRS2b has a novel role in the inhibition of EGF signaling. This was evident from the finding that FRS2b expression inhibits cell transformation induced by activated EGFR (Huang et al., 2004 (Huang et al., , 2006 Gotoh, 2009) . Although the phosphotyrosine-binding domain of FRS2b constitutively binds to EGFR regardless of EGF stimulation, FRS2b does not get phosphorylated by the activated EGFR. Instead, it inhibits EGFR autophosphorylation, which results in the inhibition of downstream signaling. Therefore, FRS2b is a unique scaffolding adaptor that serves both as a negative and a positive regulator of receptor species-dependent receptor tyrosine kinase signaling. Although the binding between FRS2b and ERK seems important for the inhibition of EGFR signaling, the precise molecular mechanisms underlying this inhibitory effect of FRS2b and the role of FRS2b in human cancer remain unclear.
MAP kinases (MAPKs), including ERK, are phosphorylated by MAPK kinases (MAPKKs), which phosphorylate various targets (for example, transcription factors and MAPK-activating protein kinases (MAPKAPs)), and are inactivated by several MAPKphosphatases (MKPs) or PTPs (Sharrocks et al., 2000; Tanoue et al., 2000; Tanoue and Nishida, 2003) . This linear cascade is strictly controlled by a specific MAPKK, MAPKAP, MKP and PTP for each MAPK. For ERK, the MAPKK is MEK1/2, the MAPKAPK is the RSK family of proteins, the MKP is MKP-3/4, and the PTP is EC-PTP. A different set of MAPKK, MAPKAP, MKP and PTP has been defined for p38, another MAPK. Almost all the MAPKKs, MAPKAPs, MKPs and PTPs that interact with the MAPK appear to have a conserved motif, called D domain, which interacts with the common docking (CD) domain on MAPK. It is thought that the strict specificity of each linear cascade involving an MAPK is partly because of the specific binding between the D domain and CD domain.
Lung cancer is a major cause of cancer related deaths in industrialized countries, and non-small cell lung cancer (NSCLC) accounts for approximately 80% of total lung cancer cases (Jemal et al., 2008) . The 5-year survival rate remains poor despite recent advances in the diagnosis and treatment. Recent studies have revealed a potential importance of EGFR tyrosine kinase signaling in development and progression of NSCLC (Baselga and Arteaga, 2005; Hynes and Lane, 2005; Sonobe et al., 2005 Sonobe et al., , 2006 . Considering the role of FRS2b for inhibition of EGFR signaling, it is hypothesized that there may be correlation between FRS2b expression in the tissues of NSCLC patients and clinicopathological features including prognosis, which may indicate a novel function of FRS2b. However, no study has documented a correlation between FRS2b expression and clinicopathological features in NSCLC.
In this study, we demonstrate that FRS2b inhibits oncogenic ErbB2-induced anchorage-independent cell growth and that it inhibits heterodimer formation between EGFR and ErbB2. We have also restricted the binding sites between FRS2b and ERK to a few amino acids on each protein. Our results suggest that the binding is mediated by the D domain and CD domain on FRS2b and ERK, respectively. Consistent with the negative feedback role for FRS2b by ERK binding, we show that EGF stimulates the translocation of ERK to the plasma membrane, resulting in the colocalization of ERK and FRS2b. Finally, a low expression level of FRS2b is significantly associated with poor prognosis in NSCLC patients, thereby providing further evidence of the role of FRS2b as a tumor suppressor.
Results

FRS2b suppresses anchorage-independent cell growth induced by oncogenic ErbB2 and inhibits heterodimer formation between EGFR and ErbB2
In order to examine whether FRS2b has an effect on another member of EGFR family, we examined whether FRS2b inhibits oncogenic ErbB2-induced anchorageindependent cell growth. As no ligands have been found for ErbB2, we used NIH3T3 cells expressing the oncogenic V659E (VE) mutant ErbB2 (ErbB2-VE), which contains a point mutation in the transmembrane domain of ErbB2 and is thus constitutively active (Bargmann and Weinberg, 1988; Akiyama et al., 1991) . Using a retroviral expression system, we expressed wild-type FRS2b or mutant FRS2b D237-252, which has decreased ERK-binding activity (Huang et al., 2006) , in these cells and control NIH3T3 cells. The transduced cells were cultured in soft agar, and anchorage-independent cell growth was analyzed. In the absence of ErbB2-VE, parental NIH3T3 cells did not produce any colonies (Figure 1a, upper panel) , whereas NIH3T3 cells expressing ErbB2-VE produced many colonies ( Figure 1a , lower panels). The number of colonies derived from cells expressing wild-type FRS2b was decreased (approximately a 50% reduction) compared with empty vector-transduced cells (Figure 1a , lower panels and 1b). When the cells were transduced with the mutant FRS2b D237-252, the number of colonies was restored to a certain extent. These results suggest that FRS2b interferes with ErbB2-VE-mediated anchorage-independent cell growth in an ERK bindingdependent manner.
It is believed that dimer formation is essential for the activation of EGFR family tyrosine kinases (Yarden and Sliwkowski, 2001) . As there may be no ligand for ErbB2, it is important for ErbB2 to heterodimerize with another member of EGFR family. Therefore, we examined the effects of the expression of FRS2b on the heterodimerization of wild-type ErbB2 or ErbB2-VE and EGFR with or without EGF stimulation. We expressed flag-tagged FRS2b and either wildtype ErbB2 or ErbB2-VE in HEK293 cells. EGFstimulated or unstimulated cell lysates were subjected 
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ErbB2-VE ( Figure 1e , lanes 5 and 7). The amount of EGFR co-immunoprecipitated with wild-type ErbB2 or ErbB2-VE was reduced in cells expressing FRS2b ( Figure 1e , compare lanes 1 and 2, lanes 3 and 4, lanes 5 and 6, and lanes 7 and 8).
We also examined whether FRS2b binds to ErbB2 using lysates from unstimulated cells. As shown in Figure 1f , FRS2b binds to ErbB2-VE and wild-type ErbB2. It is therefore likely that FRS2b binds to ErbB2 in a manner analogous to its interaction with EGFR. These results suggest that FRS2b inhibits not only EGFR but also ErbB2, another member of EGFR tyrosine kinase family, by inhibiting EGFR-ErbB2 dimerization, which leads to the inhibition of the activation of receptor tyrosine kinases.
Four arginine residues in the consensus D domain motif of FRS2b are important for interaction with ERK Although the FRS2b-ERK interaction appears to be important for the inhibitory effects of FRS2b, it is still unclear whether this interaction takes place constitutively or only transiently following EGF stimulation; in other words, whether or not the interaction depends on the activation of ERK. We expressed myc-tagged FRS2b and flag-tagged ERK in HEK293 cells and stimulated them with EGF, and cell lysates were analyzed by IP with an anti-flag antibody. As shown in Figure 2a , the amount of FRS2b protein coimmunoprecipitated with ERK was strongly increased 10 min after EGF stimulation, when the maximum level of phosphorylated and activated ERK was observed. However, it decreased to the level of unstimulated cells after 30 min. The time course of this interaction was similar to the activation level of ERK. These results suggest that the FRS2b-ERK interaction is transient in response to EGF stimulation and that the level of interaction is associated with the activation levels of ERK.
When we expressed myc-tagged FRS2b and flagtagged ERK together with MEK ca , a constitutively active mutant of MEK (Huang et al., 2006) , in HEK293 cells, the FRS2b-ERK interaction was constitutive (Figure 2a , right lane). This suggests that the activation of MEK-ERK pathway is important for the FRS2b-ERK interaction. We next examined whether MEK is included in a complex between FRS2b and ERK. EGF-stimulated or unstimulated cell lysates expressing flag-tagged FRS2b were immunoprecipitated with anti-flag antibody. As expected, ERK was co-immunoprecipitated with FRS2b in response to EGF; however, MEK was hardly detectable in the immunoprecipitates (Figure 2b ). Thus, FRS2b does not bind to MEK at detectable levels.
We previously identified amino acid residues 237-252 of FRS2b as an ERK-binding domain by progressively making deletion mutants of FRS2b from its carboxyl terminus (Huang et al., 2006) . To precisely define the binding sites of the interaction between FRS2b and ERK, we analyzed the amino acid sequence of the FRS2b protein. A 'D domain' is a consensus ERKbinding site, which consists of a cluster of basic amino acids (arginine (R) or lysine (K)) that is surrounded by hydrophobic amino acids, such as leucine (L) and/or isoleucine (I) (Sharrocks et al., 2000; Tanoue and Nishida, 2003) .
Of these amino acids, the basic amino acids are thought to be essential for binding. In the 237-252 region of FRS2b, we identified an RR motif at amino acids 250 and 251 with surrounding hydrophobic amino acids including V. We also identified an RR motif at amino acids 315 and 316 of FRS2b that is surrounded by hydrophobic amino acids including L (Figure 2c ). As these sequences appear to be a D domain, we examined whether these four R residues have a role in the FRS2b-ERK interaction. We constructed three FRS2b mutants: two mutants in which two R residues were replaced by alanine (A) residues (R250, 251A and R315, 316A) and one mutant in which all of the R residues were replaced by A residues (4RA). We expressed myc-tagged FRS2b and flag-tagged ERK, together with or without MEK ca , in HEK293 cells, and cell lysates were analyzed by IP with an anti-myc antibody. ERK was co-immunoprecipitated with wild-type FRS2b when MEK ca was expressed and ERK was activated, but not without MEK ca expression (Figure 2d , top and bottom panels). By contrast, the amount of ERK that co-immunoprecipitated with the FRS2b mutants was decreased. The reduction was strongest for the 4RA mutant, whereas the R250, 251A mutant and the R315, 316A mutant showed a moderate level of reduction. These results demonstrate that R residues 250, 251, 315 and 316 of FRS2b are essential for binding to ERK.
ERK translocates to the plasma membrane and is colocalized with FRS2b in response to EGF The above data demonstrate the molecular interaction between FRS2b and ERK. We next examined whether FRS2b and ERK were colocalized in cells. We expressed EGFR with myc-tagged wild-type FRS2b or the 4RA mutant and flag-tagged ERK in NIH3T3 cells, stimulated the cells with EGF after starvation, and analyzed the cells using immunofluorescence. Consistent with the presence of an N-terminal myristylation site, both the wild-type FRS2b protein and the 4RA mutant were localized at the plasma membrane at similar levels, and no significant change was observed with or without EGF stimulation (Figure 3a) . By contrast, in cells expressing wild-type FRS2b but not the 4RA mutant, ERK accumulated at the plasma membrane in response to EGF and colocalized with FRS2b after 10 min (Figure 3a) . We quantified the membrane localization of ERK based on the amount of the stained contour of the cells. We classified the accumulation patterns into 0-20%, 20-50% and more than 50% (Figures 3c and d) . In cells expressing wild-type FRS2b, ERK accumulated at the plasma membrane and colocalized with FRS2b transiently in response to EGF. Number of cells with 450% accumulation was rapidly increased upon EGF stimulation, reaching a peak level after 10 min and then gradually decreased (Figure 3c ). On the contrary, number of cells with 0-20% accumulation was decreased (Figures 2a and 3c) . However, the accumulation of ERK at the plasma membrane was not observed in cells expressing the 4RA mutant or in empty vector-transfected cells (Figures 3a, c and d ). All these results are consistent with the fact that ERK localizes to the plasma membrane through binding to FRS2b.
It is well-known that ERK translocates to nucleus, leading to cell proliferation by EGF stimulation (Huang et al., 2004) . Consistently, we observed increased nuclear translocation of ERK upon stimulation with EGF and it was clearly observed after 60 min in cells expressing 4RA (Figure 3b) . We quantified cells with nuclear translocation of ERK ( Figure 3e ). As we reported previously (Huang et al., 2004) , we observed that nuclear translocation of ERK was occurred in cells upon stimulation with EGF and this was inhibited by expression of FRS2b. This inhibition was not observed in cells expressing 4RA, consistent with our previous results that FRS2b mutant lacking ERK binding does not have this inhibitory effect (Huang et al., 2004) . These results are also consistent 
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ERK binds to FRS2b through a CD domain
The time course of ERK phosphorylation showed a similar pattern to binding between ERK and FRS2b  Figures 2a and 3b) . Together with the fact that the colocalization of FRS2b and ERK was observed transiently in response to EGF, it is reasonable to hypothesize that activation of ERK is important for the binding of FRS2b to ERK. We examined whether activation of ERK is important for its binding to FRS2b. We introduced point mutations in the activation loop of ERK1 (202 threonine (T)-alanine (A) and 204 tyrosine (Y)-phenylanalnine (F); TY/AF mutant). As these residues of ERK1 need to be phosphorylated by MEK for activation, the TY/AF ERK mutant is inactive (Butch and Guan, 1996) . We expressed myctagged FRS2b and flag-tagged ERK1 together with or without MEK ca in HEK293 cells, and cell lysates were analyzed by IP with an anti-flag antibody. As shown in Figure 4a , wild-type ERK1 bound strongly to FRS2b in cells expressing MEK ca , in association with the presence of phosphorylated ERK1, whereas binding between the TY/AF ERK1 mutant and FRS2b was very low. We next expressed HA-tagged FRS2b and flag-tagged ERK1 together with or without MEK ca in HEK293 cells, treated cells with MEK inhibitor U0126, and cell lysates were analyzed by IP with an anti-flag antibody. As shown in Figure 4b , the amount of FRS2b bound to ERK1 was strongly reduced by treatment with U0126. We also expressed flag-tagged FRS2b in HEK293 cells, stimulated cells with EGF in the presence or absence of U126, and cell lysates were analyzed by IP with an antiflag antibody. As shown in Figure 4c , the amount of endogenous ERK bound to FRS2b was strongly 
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reduced by treatment with U0126. Therefore, all these results indicate that activation of ERK strongly increases its binding to FRS2b.
The CD domain, which is located in the carboxylterminal region of ERK, is thought to be involved in the binding between ERK and its interacting proteins that carry a D domain. To examine the role of CD domain in the interaction between FRS2b to ERK, we constructed an ERK1 CD domain mutant in which two conserved aspartic acid (D) residues (335 and 338) were replaced by asparagine (N) (D/N mutant) (Tanoue et al., 2000) . We expressed myc-tagged FRS2b and either flag-tagged Figure 4d , the amount of FRS2b that co-precipitated with the D/N mutant was very low compared with the amount that co-precipitated with wild-type ERK1. Therefore, the ERK CD domain is important for the binding between ERK and FRS2b. We previously reported that expression of FRS2b was strongly suppressed in several brain tumor cell lines and lung cancer cell lines, compared with brain tissue or a cell line derived from normal lung tissue (Huang et al., 2006) . Although we checked many cancer cell lines, we are not able to find a cell line in which FRS2b is expressed at considerable levels. In tens of breast cancer cell lines that we examined, expression of FRS2b was found to be strongly suppressed compared with brain tissue, and there was an inverse relationship between expression levels of ErbB2 and detectable levels of expression of FRS2b (Supplementary Figure 1 and data not shown). These findings are supportive for the tumor suppressive role of FRS2b. When we expressed FRS2b in a breast cancer cell line MCF-7, in which expression levels of FRS2b were low, EGF-stimulated activation of ERK, autophosphorylation of EGFR and cell proliferation were inhibited (Supplementary Figure 2) . This result is consistent with our previous report showing these activities were inhibited by the expression of FRS2b in NIH3T3 cells (Huang et al., 2006) .
FRS2b mRNA expression and prognosis for lung cancer patients
To examine the role of FRS2b in human cancer, we analyzed the expression of FRS2b mRNA in tumor tissues of NSCLC patients. Tumor tissue obtained from 60 NSCLC patients was reviewed to assess the correlation between FRS2b mRNA expression and clinicopathological features. FRS2b mRNA expression in adenocarcinoma was significantly higher than that in non-adenocarcinoma (P ¼ 0.009) ( Table 1) . FRS2b mRNA expression was also significantly higher in lower pathologic (p)-stage samples and samples from well differentiation grades (P ¼ 0.024 and P ¼ 0.013, respectively) ( Table 1 ). FRS2b mRNA expression was associated with the tumor status including pathologic (p) T-factor and pN-factor. FRS2b mRNA expression significantly decreased as the tumor grade increased (the mean FRS2b mRNA/GAPDH mRNA: 2.342 Â 10 À2 for pT1, 0.789 Â 10 À2 for pT2 and 0.473 Â 10 À2 for pT3-4 disease; P ¼ 0.004) (Figure 5a ). FRS2b mRNA expression in tumors with lymph node involvement (pN1-3) was also reduced compared with tumors without nodal involvement (pN0) (the mean FRS2b mRNA/GAPDH mRNA: 0.656 Â 10 À2 for pN1-3 and 1.755 Â 10 À2 for pN0; P ¼ 0.046) (Figure 5b ). The 5-year survival rates of patients with FRS2b-high tumors and FRS2b-low tumors were 83.0 and 48.6%, respectively, demonstrating a significant favorable prognosis for patients with FRS2b-high tumors (log-rank, P ¼ 0.013) (Figure 6a ). When stratified by histological type, high FRS2b expression significantly correlated with a favorable prognosis for adenocarcinoma patients (log-rank, P ¼ 0.007) (Figure 6b ).
Discussion
In this study, we demonstrate that FRS2b inhibits anchorage-independent cell growth, an important criteria for cell transformation, induced by oncogenic ErbB2. We also showed that FRS2b inhibits heterodimer formation between EGF receptor and ErbB2. One of the characteristics of EGFR family members is that they efficiently heterodimerize to become activated. This is important because ErbB2, for which no ligand has been identified, can be activated by EGF, a physiological ligand for EGFR (Yarden and Sliwkowski, 2001) . It is thought that heterodimers consisting of ErbB2 and EGFR stimulate stronger signals than homodimers of EGFR. Our finding that FRS2b inhibits the biological activity of not only EGFR but also ErbB2 raises an intriguing possibility that FRS2b serves as a general inhibitor of EGFR family members. In fact, we observed that the activation of ErbB3, another EGFR family member, in response to neuregulin, a ligand for ErbB3, was inhibited by the expression of FRS2b (MW, NG, unpublished results) .
We have demonstrated that the CD domain of ERK is important for FRS2b-ERK interaction, and we have identified two regions in FRS2b that match the As FRS2a binds to ERK in a stimulus-dependent manner, it is possible that FRS2a interacts with ERK using these sequences (Lax et al., 2002) . Because of the specific binding between the D domain and the CD domain, it is likely that FRS2b is regulated specifically by ERK, but not by other MAPKs. It has been reported that binding between the D domain and the CD domain facilitates phosphorylation of the D domain-containing protein by ERK in many cases. However, we have previously reported that FRS2b is not readily phosphorylated on its threonine residues, which is in contrast to the strong threonine phosphorylation reported for FRS2a (Lax et al., 2002; Gotoh et al., 2004b ). Although it is still possible that FRS2b is phosphorylated by ERK at a low level, the phosphorylation of FRS2b by ERK may not be essential for its regulation. Similarly, a transcription factor JunB has D-domain to recruit JNK MAPK, despite lack of phosphorylation sites by JNK (Sharrocks et al., 2000) .
In response to EGF, we observed a transient localization of ERK to the plasma membrane, where it colocalized with FRS2b. This localization was abrogated in cells expressing the 4RA FRS2b mutant (a D domain mutant). It has been reported that the D-CD domain interaction has an important role in the subcellular localization of ERK (Tanoue and Nishida, 2003) . For example, MEK1 binds to ERK via the D-CD domain interaction, and MEK1 is reported to be a cytoplasmic anchor for ERK. In this study, we demonstrated that FRS2b is a plasma membrane anchor for ERK. Moreover, we confirmed that expression of FRS2b leads to inhibition of nuclear translocation of ERK in these cells. Therefore, it is possible that anchoring ERK at the plasma membrane by FRS2b contributes to the inhibition of nuclear translocation of ERK, leading to reduced cell proliferation.
Furthermore, we showed that FRS2b-ERK binding is greatly increased by the activation of ERK. It is thought that the binding between the D domain and the CD domain occurs at a different surface of ERK outside of the activation loop where ERK is phosphorylated, and therefore activated, by MEK . It is possible that activation induces a conformational change in ERK that increases its affinity for FRS2b. Then, it appears that the complex involving the receptor, FRS2b and ERK inhibits heterodimer formation of EGFR and ErbB2. This is consistent with the role of FRS2b as a negative feedback inhibitor.
We provide evidence that FRS2b may serve as a tumor suppressor in NSCLCs because a low expression level of FRS2b was associated with an advanced pathological stage, increased lymph node metastasis, and poor prognosis. Given that FRS2b is an inhibitor of EGFR family tyrosine kinases, one hypothesis is that EGFR signaling is activated in the tumor cells, which may contribute to the aggressiveness of NSCLC. In fact, gefitinib or erlotinib, an inhibitor of EGFR, is effective in NSCLC patients who carry a specific mutation in EGFR (Paez et al., 2004; Baselga and Arteaga, 2005; Hynes and Lane, 2005) . This indicates that EGFR is FRS2b inhibits ErbB family and is prognostic for NSCLC D Iejima et al critical for tumorigenesis, at least in some cases. It is also possible that, with a high level of FRS2b expression. EGFR signaling is downregulated in tumor cells and that these tumor cells are unlikely to require EGFR signaling. Because it is thought that inhibitors targeting EGFR family members are effective when tumor cells require EGFR signaling, tumor cells with a high level of FRS2b expression may not be highly responsive to such drugs. In particular, the expression level of FRS2b was found to be higher in the adenocarcinoma tissue than in the non-adenocarcinoma tissue and higher in female patients than in male patients. As the EGFR mutation associated with gefitinib sensitivity is frequently observed in the tissue of adenocarcinoma and/or female patients, the level of FRS2b expression might stratify such patients further to predict the effectiveness of gefitinib therapy. Therefore, it will be interesting to test the usefulness of FRS2b as a biomarker that predicts the effectiveness of treatment to drugs that target EGFR family. However, to adequately test this hypothesis, an extensive analysis of a large cohort of patients will be required.
Taken together, we provide molecular mechanisms whereby FRS2b acts as a feedback inhibitor for signal transduction through EGFR family tyrosine kinases. We also provide supportive evidence that FRS2b serves as a tumor suppressor in NSCLC. Our finding raises an intriguing possibility that FRS2b would be a premising molecular target or/and a diagnostic biomarker for tumors that are addicted by EGFR family tyrosine kinases. An important avenue for future research would be to analyze knock out mice of Frs2b gene to have further insights into the functions of FRS2b in vivo.
Materials and methods
Soft agar colony formation assays NIH3T3 cells expressing wild type or mutant ErbB2 or parental cells were transduced with retrovirus-expressing FRS2b or D237-252. The cells were seeded at 5 Â 10 4 cells per 35 mm dish in 2 ml of DMEM containing 10% new born calf serum and 0.36% agarose on the top of an existing 0.72% FRS2b inhibits ErbB family and is prognostic for NSCLC D Iejima et al agarose layer in triplicate. After 3 weeks, cell colonies 40.1 mm in diameter were counted.
Patients and tissue samples Primary lung cancer tissue was obtained from 60 patients with pathologic (p) stage I-III NSCLC, who were operated on at Kyoto University Hospital between 1996 and 1998. The p-stage was determined using the current TNM classification. The histological type and the grade of cell differentiation were determined according to the classification by the World Health Organization. All samples were obtained after informed consent was provided and were immediately snap-frozen in liquid nitrogen and stored at À80 1C until use. For histological examination, samples were fixed in 10% (v/v) formalin and then embedded in paraffin. Serial 4-mm sections were prepared from each sample and were used for hematoxylin and eosin staining. This study was reviewed and approved by the ethics committee of the Graduate School and Faculty of Medicine, Kyoto University.
Statistical analysis
The Stat View 5.0 statistical software package was used for all statistical analyses. The w 2 test was used to compare counts. Continuous data between two groups were compared using Student's t-test if the distribution of samples was normal or the Mann-Whitney U-test if the sample distribution was asymmetrical. Continuous data among three or more groups were compared using an analysis of variance if the distribution of samples was normal or the Kruskal-Wallis H-test if the sample distribution was asymmetrical. The postoperative survival rate was analyzed using the Kaplan-Meier method, and the differences in survival rates were assessed using the log-rank test. Differences were considered significant when the P-value was o0.05.
